Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Schizophrenia Clinical Trial

— SERENITY I  

Official title:

A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04268303
• Other study ID #: BXCL501-301
• Status: Completed
• Phase: Phase 3
• Start date: January 24, 2020
• Est. completion date: May 6, 2020

Study information

• Verified date: May 2023
• Source: BioXcel Therapeutics Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.

Description:

The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg, 120µg BXCL501, or placebo. Male and female adults with acute agitation associated with schizophrenia, schizoaffective disorder, or schizophreniform disorder will be enrolled. Eligible subjects may be identified in outpatient clinics, mental health, psychiatric or medical emergency services including medical/psychiatric observation units, or as newly admitted to a hospital setting for acute agitation or already in hospital for chronic underlying conditions. Subjects will be domiciled in a clinical research setting or hospitalized to remain under medical supervision while undergoing screening procedures to assess eligibility. Efficacy and safety assessments will be conducted periodically before and after dosing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 380
• Est. completion date: May 6, 2020
• Est. primary completion date: May 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

A subject will be eligible for inclusion in the study if he or she meets the following

criteria:

1. Male and female patients between the ages of 18 to 75 years, inclusive.

2. Patients who have met DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder.

3. Patients who are judged to be clinically agitated at Screening and Baseline with a total score of = 14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).

4. Patients who have a score of = 4 on at least 1 of the 5 items on the PEC at Baseline.

5. Patients who read, understand, and provide written informed consent.

6. Patients who are in good general health prior to study participation as determined by a detailed medical history, physical examination, 12-lead ECG with rhythm strip, blood chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator.

7. Participants who agree to use a medically acceptable and effective birth control method Exclusion Criteria:

A subject will be excluded from the study if he or she meets the following criteria:

1. Patients with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse (with the exception of THC) during urine screening.

2. Use of benzodiazepines, hypnotics and anti-psychotic drugs in the 4 hours before study treatment.

3. Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin) or other prohibited medications.

4. Patients who are judged to be at significant risk of suicide

5. Female patients who have a positive pregnancy test at screening or are breastfeeding.

6. Patients who have hydrocephalus, seizure disorder, or history of significant head trauma, stroke, transient ischemic attack, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease or focal neurological findings.

7. History of syncope or other syncopal attacks, current evidence of hypovolemia, orthostatic hypotension.

8. Patients with laboratory or ECG abnormalities considered clinically significant by the investigator.

9. Patients with serious or unstable medical illnesses.

10. Patients who have received an investigational drug within 30 days prior to the current agitation episode.

11. Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving DEX.

Related Conditions & MeSH terms

• Agitation
• Mood Disorders
• Psychomotor Agitation
• Psychotic Disorders
• Schizo Affective Disorder
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorders

Intervention

Drug:
• Sublingual film containing dexmedetomidine (BXCL501)
Sublingual film containing dexmedetomidine (BXCL501)
• Placebo Film
Placebo Film for BXCL501

Locations

Country	Name	City	State
United States	BioXcel Clinical Research Site	Austin	Texas
United States	BioXcel Clinical Research Site	Berlin	New Jersey
United States	BioXcel Clinical Research Site	Cerritos	California
United States	BioXcel Clinical Research Site	Charleston	South Carolina
United States	BioXcel Clinical Research Site	Chicago	Illinois
United States	BioXcel Clinical Research Site	Culver City	California
United States	BioXcel Clinical Research Site	DeSoto	Texas
United States	BioXcel Clinical Research Site	Gaithersburg	Maryland
United States	BioXcel Clinical Research Site	Las Vegas	Nevada
United States	BioXcel Clinical Research Site	Little Rock	Arkansas
United States	BioXcel Clinical Research Site	Long Beach	California
United States	BioXcel Clinical Research Site	Marlton	New Jersey
United States	BioXcel Clinical Research Site	Miami Lakes	Florida
United States	BioXcel Clinical Research Site	Orange	California
United States	BioXcel Clinical Research Site	Richardson	Texas

Sponsors (2)

Lead Sponsor	Collaborator
BioXcel Therapeutics Inc	Cognitive Research Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score	The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).	Baseline and 2 hours
Secondary	Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score Over Time	Effect on agitation onset was measured by change from baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) total score. The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).	Baseline and 10, 20, 30, 45, 60, 90 minutes post-dose

External Links

•   Journal Article